PSMD‐2: A fully automated marker for longitudinal assessment of cerebrovascular white matter injury
PSMD-2 provides improved sensitivity to detect SVD-related brain changes compared to the previous PSMD version, leading to smaller required sample sizes for clinical trials. Thus, PSMD-2 is a key candidate as surrogate endpoint in SVD-targeting trials, for monitoring disease progression and for capturing comorbid vascular brain changes in AD in longitudinal settings.
Authors
- Julie W. Rutten (ORCID: https://orcid.org/0000-0003-3250-7263)
- Anna Kopczak (ORCID: https://orcid.org/0000-0002-5037-2342)
- Gido Gravesteijn (ORCID: https://orcid.org/0000-0002-2610-8728)
- Benno Gesierich (ORCID: https://orcid.org/0000-0003-2842-7105)
- Saskia Lesnik Oberstein
- Nicolai Franzmeier (ORCID: https://orcid.org/0000-0001-9736-2283)
- Anna Dewenter
- Marco Duering
- Hugh S Markus
Institutions
- University of Basel (CH)
- University of Cambridge (GB)
- LMU Klinikum (DE)
- Munich Cluster for Systems Neurology (DE)
- Ludwig-Maximilians-Universität München (DE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_100286
- Primary Topic
- Cerebrovascular and genetic disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00